← All trials
NCT06496282
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2024
- Primary completion
- May 31, 2026
- Completion date
- Jul 31, 2026
- First posted
- Jul 11, 2024
- Last posted
- Jul 11, 2024
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ThailandLead sponsor
- Silpakorn UniversityCollaborator
- Government of ThailandOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.